Publications by authors named "B J Monk"

Claim this Profile
D
Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer.
Bradley J Monk, Robert L Coleman, David M O'Malley, Kathleen N Moore, Antonio González-Martín

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The molecular basis of intrinsic resistance to azoles in .
Michaela Lackner, Stephanie Toepfer, Mikhail V Keniya, Carlos Lax, Francisco E Nicolas, Brian C Monk

Antimicrob Agents Chemother· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrinsic resistance to short-tailed azoles in the basal fungus : functional analysis of Cyp51 isoforms and amino acid substitutions.
K Rosam, M V Keniya, L-M Zenz, C Müller, B Sarg, B C Monk

Front Microbiol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201.
Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, Véronique D'Hondt, Bradley J Monk

Future Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study.
R S Kristeleit, S Ghamande, A Lisyanskaya, A Oaknin, E Prendergast, B J Monk

Ann Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis